Amgen 2004 Annual Report Download - page 19

… and many more moments to come
Amgen’s Research and Development leaders, a few of whom
are pictured above, work to transform the science of today into
the powerful medicines of tomorrow. From left to right: Ruth
Lightfoot-Dunn, vice president, Preclinical Safety Assessment; Paul
Pearson, vice president, Pharmacokinetics and Drug Metabolism;
Chris Fibiger, vice president and global head, Neuroscience;
Susan Hershenson, vice president, Pharmaceutics; and Glenn
Begley, vice president, Hematology and Oncology Research.
execution that move medicine forward. Those are the
moments that matter the most — to patients, to healthcare
providers, and to Amgen.
In our fi rst 25 years, Amgen has been fortunate to play
a part in many such moments. While we can’t predict what
extraordinary advances in medical care will be made possible
by new technologies and discoveries in the next 25 years, we
intend to contribute to as many of them as we can.
We expect many more changes as we head into the
future — but some things will not change. Amgen will
continue to combine visionary science and innovation with
rational decision-making and rigorous execution — because
our pipeline is our future. And we will never lose sight of
our mission to serve patients — because that’s what makes
it all worthwhile.
The history of scientifi c progress is
often told as a series of breakthrough
moments. But as any scientist can
tell you, those rare moments of success
are woven together with countless
moments of disappointment — of leads
that led nowhere, of great ideas that
never became more than ideas.
Disappointment and success, effort
and end result — a complex braid of
moments makes up the beautiful pattern
of scientifi c inquiry. Every moment has
a lesson to teach. Ultimately, it’s the
moments of real insight that come
from perseverance, determination, and
Amgen 2004 Annual Report page 17